达格列净联合二甲双胍治疗2型糖尿病的效果观察

Efficacy of Dapagliflozin Combined with Metformin in the Treatment of Type 2 Diabetes Mellitus

目的探讨对2型糖尿病患者采用达格列净+二甲双胍药物完成治疗后获得临床效果。方法选取2020年10月—2021年10月广宁县人民医院100例2型糖尿病患者,按照随机数字表法分为常规组和研究组,各50例。常规组采用格列齐特缓释片+二甲双胍缓释片治疗,研究组采用达格列净+二甲双胍缓释片治疗。比较两组患者治疗结果。结果研究组治疗总有效率(98.00%)高于常规组(84.00%),差异有统计学意义(χ^(2)=5.983,P<0.05)。治疗后,研究组三酰甘油、低密度脂蛋白、总胆固醇以及体质指数均低于常规组,差异有统计学意义(P<0.05)。治疗后,研究组空腹血糖、糖化血红蛋白、餐后2 h血糖水平均低于常规组,差异有统计学意义(P<0.05)。结论达格列净+二甲双胍缓释片联合应用,可显著提高患者治疗效果,显著改善血脂水平以及体质量,有效降低血糖水平,促进2型糖尿病患者总体预后水平改善。

Objective To investigate the clinical effect of dapagliflozin plus metformin in patients with type 2 diabetes.Methods 100 patients with type 2 diabetes in Guangning County People's Hospital from October 2020 to October 2021 were selected and divided into routine group and study group according to random number table,with 50 cases in each group.The routine group was treated with gliclazide sustained-release tablets and metformin sustained-release tablets,while the study group was treated with daggliflozin and metformin sustained-release tablets.Compared the treatment results of two groups of patients.Results The total effective rate of the study group(98.00%)was higher than that of the routine group(84.00%),the difference was statistically significant(χ^(2)=5.983,P<0.05).After treatment,the levels of triglycerides,low-density lipoprotein,total cholesterol,and body mass index in the study group were lower than those in the routine group,the difference was statistically significant(P<0.05).After treatment,the fasting blood glucose,glycated hemoglobin,and 2-hour postprandial blood glucose levels in the study group were significantly lower than those in the routine group,the difference was statistically significant(P<0.05).Conclusion The combined application of dapagliflozin and metformin sustained-release tablets can significantly improve the therapeutic effect of patients,significantly improve the level of blood lipid and body mass,effectively reduce the level of blood glucose,and promote the improvement of the overall prognosis of patients with type 2 diabetes.